ADX-629 + Placebo

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ethanol Intoxication

Conditions

Ethanol Intoxication

Trial Timeline

Nov 15, 2021 → May 29, 2022

NCT ID

NCT05487404

About ADX-629 + Placebo

ADX-629 + Placebo is a phase 1/2 stage product being developed by Aldeyra Therapeutics for Ethanol Intoxication. The current trial status is completed. This product is registered under clinical trial identifier NCT05487404. Target conditions include Ethanol Intoxication.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05392192	Phase 2	Completed	Apr 7, 2022	Apr 13, 2023	Chronic Cough
NCT05487404	Phase 1/2	Completed	Nov 15, 2021	May 29, 2022	Ethanol Intoxication
NCT04847544	Phase 2	Completed	Mar 31, 2021	Oct 15, 2021	Covid19
NCT04728711	Phase 2	Completed	Jan 9, 2021	Jan 18, 2022	Atopic Asthma

Competing Products

1 competing product in Ethanol Intoxication

See all competitors

Product	Company	Stage	Hype Score
tasimelteon + Ethanol + Placebo ethanol	Vanda Pharmaceuticals	Phase 1	19